283: A CRISPR milestone, algorithms amok, & biotech mixology
The Readout Loud
00:00
Targeting RNA for Future Medicines
Michael Gilman, CEO of Arrakis Therapeutics, discusses their work in developing oral drugs that target RNA, including messenger RNAs, disease-specific RNAs, and non-coding RNAs. They talk about their progress in targeting MIQ as a drug and their discovery of compounds that block translation of RNA. They also highlight the significance of RNA as a target for future medicines.
Transcript
Play full episode
